AKRO:NSD-Akero Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.72

Change

0.00 (0.00)%

Market Cap

USD 3.35B

Volume

0.59M

Analyst Target

USD 58.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing AKRO

LFSC F/m Emerald Life Sciences.. 6.24 % 0.00 %

N/A

USD 0.05B
SURI Simplify Propel Opportuni.. 4.39 % 0.00 %

N/A

N/A
BBC Virtus LifeSci Biotech Cl.. 1.59 % 0.79 %

N/A

USD 0.01B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

N/A

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.56% 95% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.56% 95% A 96% N/A
Trailing 12 Months  
Capital Gain 69.12% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.12% 92% A 93% A
Trailing 5 Years  
Capital Gain 101.51% 85% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 101.51% 85% B 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 40.17% 77% C+ 85% B
Dividend Return 40.17% 77% C+ 85% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 126.09% 32% F 17% F
Risk Adjusted Return 31.86% 86% B+ 64% D
Market Capitalization 3.35B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector